Pharmacokinetics of zidovudine and didanosine during combination therapy. 1995

G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
Department of Pharmacy Practice, State University of New York at Buffalo 14260, USA.

While the combination of zidovudine and didanosine is used in HIV-infected patients with more advanced disease, the possibility of a pharmacokinetic interaction between these two drugs remains controversial. Zidovudine doses of 50, 100, and 200 mg, combined with 67, 167, and 250 mg of didanosine were evaluated in 11 asymptomatic HIV-infected patients after receiving 24 weeks of combination therapy in AIDS Clinical Trials Group protocol 143. The pharmacokinetic parameters of zidovudine and didanosine were similar to those obtained with each drug given as monotherapy in other previously published studies. The renal clearance and urinary recovery of glucuronidated zidovudine was reduced when zidovudine was given in combination with didanosine, possibly due to competition for renal tubular secretion. These data suggest that no clinically important pharmacokinetic interaction occurs when zidovudine and didanosine are given together.

UI MeSH Term Description Entries
D008297 Male Males
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016049 Didanosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. 2',3'-Dideoxyinosine,Dideoxyinosine,ddI (Antiviral),NSC-612049,Videx,2',3' Dideoxyinosine,NSC 612049,NSC612049

Related Publications

G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
January 1996, Antiviral research,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
October 1993, Annals of internal medicine,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
February 1994, Pediatrics,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
January 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
November 1997, Antimicrobial agents and chemotherapy,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
November 2000, AIDS (London, England),
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
March 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
June 1998, AIDS (London, England),
G D Morse, and M J Shelton, and M Ho, and L Bartos, and M DeRemer, and M Ragni
January 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Copied contents to your clipboard!